|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
none
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:CEO
|
gptkb:Bassil_I._Dahiyat
|
|
gptkbp:clinicalTrials
|
gptkb:XmAb®14045
gptkb:XmAb®_technology
gptkb:XmAb®13676
gptkb:XmAb®18087
gptkb:XmAb®20717
Phase 1
Phase 2
Phase 3
|
|
gptkbp:collaborations
|
academic institutions
research organizations
|
|
gptkbp:employees
|
approximately 200
|
|
gptkbp:focus
|
therapeutics
|
|
gptkbp:founded
|
1997
|
|
gptkbp:founder
|
gptkb:Bassil_I._Dahiyat
|
|
gptkbp:headquarters
|
gptkb:Monrovia,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xencor, Inc.
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:investmentFocus
|
2013
various venture capital firms
|
|
gptkbp:keyPeople
|
gptkb:John_D._McCamant
gptkb:David_A._H._Hwang
gptkb:Bassil_I._Dahiyat
Michael A. McGowan
Robert A. McGowan
|
|
gptkbp:location
|
gptkb:California
|
|
gptkbp:market
|
$1 billion (2021)
|
|
gptkbp:netIncome
|
$-30 million (2020)
|
|
gptkbp:partnerships
|
gptkb:Bristol-Myers_Squibb
gptkb:Merck_&_Co.
gptkb:Amgen
Celgene
|
|
gptkbp:patentCitation
|
over 100
|
|
gptkbp:products
|
gptkb:XmAb®_antibodies
bispecific antibodies
engineered cytokines
|
|
gptkbp:researchFocus
|
cancer
autoimmune diseases
infectious diseases
|
|
gptkbp:revenue
|
$50 million (2020)
|
|
gptkbp:specialization
|
antibody engineering
|
|
gptkbp:stockSymbol
|
XNCR
|
|
gptkbp:subsidiary
|
none
|
|
gptkbp:totalGoals
|
$200 million (2020)
$300 million (2020)
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.xencor.com
|